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ABSTRACT
Increasing maternal obesity is a challenge that has an impact on all aspects of female reproduction.
Lean and obese pregnant women gain similar fat mass, but lean women store fat in the lower-body
compartment and obese women in central compartments. In the non-pregnant, central storage
of fat is associated with adipocyte hypertrophy and represents a failure to adequately store
excess fatty acids, resulting in metabolic dysregulation and ectopic fat accumulation (lipotoxicity).
Obese pregnancy is associated with exaggerated metabolic adaptation, endothelial dysfunction
and increased risk of adverse pregnancy outcome. We hypothesize that the preferential storage of
fat in central rather than ‘safer’ lower-body depots in obese pregnancy leads to lipotoxicity. The
combination of excess fatty acids and oxidative stress leads to the production of oxidized lipids,
which can be cytotoxic and inﬂuence gene expression by acting as ligands for nuclear receptors.
Lipid excess and oxidative stress provoke endothelial dysfunction. Oxidized lipids can inhibit
trophoblast invasion and inﬂuence placental development, lipid metabolism and transport and
can also affect fetal developmental pathways. As lipotoxicity has the capability of inﬂuencing both
maternal endothelial function and placental function, it may link maternal obesity and placentally
related adverse pregnancy outcomes such as miscarriage and pre-eclampsia. The combination of
excess/altered lipid nutrient supply, suboptimal in utero metabolic environment and alterations in
placental gene expression, inﬂammation and metabolism may also induce obesity in the offspring.
HYPOTHESIS
The 70–100% increase in maternal obesity over the
last decade has had ramiﬁcations for all aspects of
female reproduction, with maternal adiposity strongly
associated with an increased risk of essentially all
maternal and fetal complications [1]. Our hypothesis is
that,inleanpregnantwomen,fattyacidsrequiredforfetal
growth are efﬁciently stored and mobilized from lower-
body fat depots. In obese pregnant women, lower-body
fat depots are replete and/or there is a preference
to store fat centrally with the potential of fatty acid
spillover and lipotoxicity. Lipotoxicity leads to maternal
endothelial dysfunction, decreases trophoblast invasion
and inﬂuences placental metabolism and function. This
is the pathological link between maternal obesity and
adverse ‘metabolic’ pregnancy outcomes such as GDM
(gestational diabetes mellitus), pregnancy-induced
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hypertension and pre-eclampsia, and may have conse-
quences for the programming of obesity in the offspring.
BODY FAT DISTRIBUTION, METABOLISM
AND LIPOTOXICITY IN THE NON-PREGNANT
Human body fat compartments can be classiﬁed
pragmatically as lower-body subcutaneous fat, upper-
body subcutaneous fat and intra-abdominal/visceral fat
[2]. The roles of these different depots in producing and
storing fatty acids has been reviewed recently [2]. The
accepted view is that visceral fat is associated with an
abnormal metabolic and adipokine proﬁle. However,
upper-body subcutaneous and visceral fat stores are
often not differentiated and the relative contributions
of each depot to metabolic dysregulation is unclear
[2]. Upper-body subcutaneous fat is relatively resistant
to insulin suppression of lipolysis and is estimated to
be the source of approx. 60% of circulating NEFAs
(non-esteriﬁedfattyacids). Conversely,lower-bodyfatis
much more sensitive to insulin suppression of lipolysis,
contributing only 15–20% of circulating NEFAs.
Consistent with these site-speciﬁc functional differences,
lower-body fat (assessed by computed tomography) is
independently associated with a reduced risk of lipid
and carbohydrate metabolic dysregulation [3], and larger
depots of lower-body adipose tissue are associated with
more efﬁcient storage of dietary fat [2]. Large population
studies in women over 40 years of age have demonstrated
that central adiposity (i.e. waist circumference) increases
with age and, independently of age, with parity [4].
Obesity is associated with upper-body adipose cell
enlargement in adults (hypertrophic obesity) and adipose
cell size is correlated with whole-body insulin resistance.
Hypertrophic obesity results in reduced uptake and
storage of fatty acids along with increases in lipolysis,
inﬂammatory cell inﬁltration and adipokine secretion
[2]. Furthermore, the number of pre-adipocytes in
abdominal subcutaneous adipose tissue capable of
undergoing differentiation to adipose cells is reduced
in hypertrophic obesity [5]. Thus this large capacity
‘sink’ for fatty acids is effectively replete and there is
NEFA spillover into the circulation, promoting ectopic
fat accumulation in extra-adipose tissues such as liver,
muscle and heart [5]. This phenomenon of NEFA
spillover is termed lipotoxicity. When the intracellular
accumulation of fatty acids in these ectopic sites exceeds
theabilityofthecellstoutilizethefattyacidsthencellular
dysfunction occurs. Lipotoxic consequences involve not
onlyfattyacids,butalsometabolitesofcholesterol.Inthe
liver, for example, the abnormal or excessive oxidation
of fatty acids leads to ROS (reactive oxygen species)
production,disturbancesincellularmembranefattyacids
and phospholipid composition, alterations in cholesterol
content and changes in ceramide signalling [6].
OXIDATIVE STRESS AND HIGH LIPID
CONCENTRATIONS LEAD TO ENDOTHELIAL
DYSFUNCTION
Obesity is associated with oxidative stress and high levels
of ROS [7]. Oxidative stress may arise from intracellular
accumulation of triacylglycerols (triglycerides) having
an impact on mitochondrial efﬁciency, resulting in
accumulation of electrons within the electron transport
chain which react with oxygen to form superoxide
radicals. The combination of high lipid levels and
oxidative stress leads to the production of three
types of oxidized lipid product with harmful effects:
lipid peroxides, oxidized lipoproteins and oxysterols.
ElevatedplasmaNEFAlevelscaninducenitroxideradical
formation in smooth muscle and endothelial cells, induce
respiratory burst in white cells and serve as substrates for
oxidation themselves, leading to the propagation of lipid
peroxides. High plasma triacylglycerol concentrations
lead to formation of small-dense LDL (low-density
lipoprotein), a highly atherogenic lipoprotein particle
readily susceptible to oxidation forming OxLDL
(oxidized LDL). In addition to oxidized fatty acids,
OxLDLcontainsoxysterols.Directattackoncholesterol
by ROS can lead to formation of the relatively stable 7α-
and 7β-hydroxycholesterol, 7-ketocholesterol and
5,6-epoxycholesterol [8,9]. High intracellular levels of
cholesterol can lead to tissue oxysterol production [e.g.
22(R)-hydroxycholesterol and 24(S)-hydroxychole-
sterol] via speciﬁc enzymes in liver, brain and macro-
phages, and these oxysterols are detectable in plasma
[8]. Plasma oxysterol concentrations are raised in the
metabolicsyndrome,diabetesandhypercholesterolaemia
[10].Inadolescentfemales,oxysterolscorrelatewithBMI
(body mass index), waist circumference and fasting in-
sulin,andweresuggestedtobeearlymarkersofoxidative-
stress-mediated metabolic dysregulation [11]. Intracellu-
lar oxysterols may have both beneﬁcial and detrimental
effects [8]. They can decrease cholesterol biosynthesis via
interaction with SREBP-1c (sterol-regulatory-element-
binding protein-1c) and are also potent transactivators
of the nuclear receptors LXR (liver X receptor) α and
β [12]. LXRα is involved in the regulation of steroid
hormone biosynthesis, bile acid synthesis, conversion
of lanosterol into cholesterol, cellular cholesterol efﬂux
and lipid-mobilizing proteins such as CETP (cholesteryl
ester transfer protein) [8]. Oxysterols, however, can be
toxic to cells inducing inﬂammation, oxidative stress and
apoptosis [8,12]. Thus there is ample evidence to link
oxidative lipid products to metabolic dysregulation.
Thereisevidence that triacylglycerol-richlipoproteins
play a role in endothelial dysfunction [13]. OxLDL
induces PAI-1 (plasminogen-activator inhibitor-1) ex-
pression in endothelial cells [14]. Long-term NEFA
elevationresultsinreducedinsulin-mediatedvasodilation
[2]. Oxysterols can induce expression of inﬂammatory
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markers in endothelial cells via LXR-independent
mechanisms [15] and may be damaging to vascular
endothelium via both oxidative and inﬂammatory means
[9,16]. Lipid effects on vascular endothelium may be
direct or via ROS generation. NEFAs can directly
inhibit NO bioavailability [17], and activate NADPH
oxidase and the mitochondrial electron transport chain
to generate superoxide [18]. Effects of OxLDL on
endothelial cells may also be via NADPH oxidase ROS
production [14]. There is substantial evidence supporting
the presence of endothelial dysfunction in obesity [17],
including increased NADPH oxidase expression in
vascular endothelial cells, and evidence of endothelial
oxidative stress [19]. There is a speciﬁc relationship with
upper-body obesity, with higher waist/hip ratio an im-
portant independent positive predictor of ﬂow-mediated
dilatation [20] and arterial stiffness [21]. Lower-body fat
has no association (or a weak inverse association) with
arterial stiffness [21]. These results indicate that lower-
body fat may be protective against vascular dysfunction.
CHANGES IN FAT MASS AND DISTRIBUTION
DURING PREGNANCY
In pregnancy, total body fat increases from the ﬁrst
trimester to parturition with a peak in the second
trimester [22], and there is an increase in the intra-
abdominal visceral fat compartment [23]. Obese women
show similar or smaller increases in total weight, fat
mass, percentage fat and total body fat than lean women
[24–27]. Studies of skinfold thicknesses [26,27] show
that obese women put on more fat in the upper-body
compartment (suprailiac and subscapular skinfold), but
that lean women put on more fat in the lower-body
compartment (mid-thigh skinfold). Non-pregnant
women with lower-body obesity are more efﬁcient at
storing systemic NEFAs in lower-body adipose depots
thanwomenwithupper-bodyobesity[28],andthiscould
be interpreted as ‘pear-shaped’ women being efﬁcient at
storing fat in lower-body depots that provide protection
against metabolic risk and endothelial dysfunction.
METABOLIC DYSREGULATION, OXIDATIVE
STRESS AND ENDOTHELIAL DYSFUNCTION
IN OBESE PREGNANCY
Healthy pregnancy is associated with lipid mobilization
(increases in plasma cholesterol and triacylglycerols),
changes in insulin resistance (a gestational increase
in insulin resistance) and improvement in endothelial
function [29]. In maternal obesity, there is an exaggerated
lipid response [30], a greater degree of insulin resistance
[30] and less improvement in endothelium-dependent
microvascularfunction[31].Therelativeendothelialdys-
functioninobesepregnancyisinpartexplainedbyaltered
levels of plasma cytokines [IL (interleukin)-6 and IL-10]
withobesity[31].Lipidperoxidesareincreasedinhealthy
pregnancy[32],butfewﬁndingsareavailableonoxidative
stress in obese pregnancy. An association between
maternal BMI and also maternal cholesterol levels and
the oxidizability of LDL has been observed [33]. In non-
pregnant Type 2 diabetics, high plasma oxysterol levels
are particularly observed when plasma LDL levels are
above approx. 3.6 mmol/l [10], a level that is exceeded
in overweight and obese women in later pregnancy.
Although the literature on oxysterols during pregnancy
is extremely limited, gestational increases and further
increases with maternal diabetes have been reported [34].
CONSEQUENCES OF LIPOTOXICITY IN
PREGNANCY
Pregnant women with familial hypercholesterolaemia
have evidence of endothelial activation [35] and increased
uteroplacental vascular resistance [36]. In pregnancies
complicated by GDM, women are insulin-resistant [37],
havehyperlipidaemia[30],increasedoxidativestress[38],
increasedLDLsusceptibilitytooxidation[33]andpoorer
endothelial function than control women [39]. These
two ‘extreme’ metabolic conditions (GDM and familial
hypercholesterolaemia),inconjunctionwiththeresultsin
the non-pregnant population relating high lipid levels to
oxidative stress and endothelial dysfunction, suggest that
lipid abnormalities arising from NEFA or cholesterol ex-
cess may be responsiblefor the observed endothelial dys-
functionofobesepregnancy.Thegenerationofoxysterols
underlipotoxicconditionsalsohaspotentialimplications
for placental development and function. Oxysterols are
ligands for LXRα and β which are expressed by human
placenta and may have an impact on lipid transport
and metabolism. OxLDL inhibits trophoblast invasion
potentially via oxysterol activation of LXRβ [40]. Col-
lectively, these pathways may contribute to the observed
increase in placental complications in obese pregnancy.
POTENTIAL IMPACT ON OFFSPRING
Therearealsoimmediate[1]andlong-termconsequences
of obese pregnancy for the offspring, including potential
programming of future obesity [41,42]. Oxysterols are
involved in Hedgehog signalling pathways, disruption
of which are associated with structural defects [43].
LXRs have been proposed to be important in placental
cholesterol transport from mother to fetus [44], and
synthetic LXR agonists increase fatty acid synthesis in
trophoblast cell lines [45]. In the hyperlipidaemic states
of Type 1 diabetes and GDM, placental expression of
genes coding for the transport and activation of fatty
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Figure 1 Fatty acid metabolism in pregnancy
A central fat accumulation during pregnancy leads to fatty acid overspill from adipose depots and lipotoxicity. Lipotoxic effects include maternal endothelial dysfunction,
decreased trophoblast invasion and altered placental metabolism. These may result in adverse pregnancy outcome (such as pre-eclampsia or miscarriage) and
programming of obesity in the offspring. A lower-body fat accumulation allows ‘safe’ storage of fatty acids and a normal metabolic and physiological adaptation to
pregnancy with appropriate nutrient transfer to the offspring. TG, triacylglycerol.
acids are up-regulated and, in GDM placenta, there
is also a selective up-regulation of genes involved in
pathways for intracellular lipid biosynthesis [46]. In
primary trophoblasts, insulin and NEFAs enhance the
formation of fatty acid droplets [46,47]. Placentae from
obese pregnancy have macrophage accumulation and
inﬂammation in an analogous way to adipose tissue
[48]. Thus the placenta is another likely site of ectopic
fat accumulation in obese pregnancy but with a ﬁnite
capacity, which, if exceeded, e.g. due to a maternal
high-fat diet, may induce lipotoxicity in the fetus [42,49].
SUMMARY (Figure 1)
Lower-body adipose tissue depots are insulin-sensitive
and they can efﬁciently store fat. Healthy pregnant
women store fat accumulated during pregnancy pre-
dominately in lower-body depots, and this is associated
with a benign maternal adaptation of metabolism
and physiology to pregnancy and a preservation of
endothelialfunction.Incontrast,upper-bodyfatcontains
hypertrophicadipocytesandisrelativelyinsulin-resistant
and in excess (i.e. in ‘apple-shaped’ women) results in
increased lipolysis of upper-body triacylglycerol stores
and increased adipokine secretion. Central obesity is also
associated with fatty acid excess and ectopic fat accu-
mulation in liver, pancreas and placenta. Obese women
therefore have a predisposition to lipotoxicity, metabolic
dysregulation and inﬂammation, which may be exagger-
ated by the accumulation of further fat during pregnancy.
Underconditionsofoxidativestress,excesslipidsbecome
oxidized to form lipid peroxides, oxidized lipoproteins
and oxysterols. These oxidized lipid mediators are
cytotoxic and can act as ligands for nuclear receptors
involved in key metabolic and developmental pathways,
whichmayadverselyaffectmaternalendothelialfunction,
trophoblast invasion and placental function. Thus
oxidizedlipidproductsmaybethelinkbetweenmaternal
obesity and placentally related adverse pregnancy
outcomes such as miscarriage and pre-eclampsia. The
combination of excess lipid nutrient supply, suboptimal
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in utero metabolic environment and the incapacity of
the placenta to effectively buffer excessive fatty acids
may trigger adaptive pathways which ultimately result
in increased percentage body fat and propensity to future
obesity in the offspring of obese mothers.
TESTING THE HYPOTHESIS
As the consequences of lipotoxicity in pregnancy have
both potential impact on pregnancy outcome and
have far-reaching consequences for offspring health, a
study of the degree, causes and impact of lipotoxicity in
obese mothers is warranted.
An understanding of the functionality of visceral,
upper-body subcutaneous and lower-body subcutaneous
adipose tissue in pregnancy with respect to lipolysis
(basal and stimulated), insulin resistance and adipokine
production is required. There are few data on the
measurement of oxidative stress in obese pregnancy
and assessment of lipid peroxides, oxidized lipo-
proteins and oxysterols. In order to link lipotoxic
mediators to adverse pregnancy outcome, studies
which test the relationship between circulating markers
of lipotoxicity and endothelial function should be
undertaken. To test whether altered fat distribution
underlies or contributes to lipotoxicity in pregnancy
a comparison of metabolic response to pregnancy,
endothelial function and placental function in women
matched for BMI but with different fat distributions
(‘apples’ compared with ‘pears’) would be informative.
An epidemiological assessment of the impact of lower-
body compared with upper-body fat distribution on risk
of adverse pregnancy outcome should be undertaken.
Maternal age is increasing and, at least in women over
40 years of age, is positively associated with central
adiposity. Thus a higher proportion of women may be
startingpregnancywithhigherreservesofupper-bodyfat
and, linked to this, lower reserves of safe fat depots. An
investigation into fat distribution associated with parity
and age in women of child-bearing age would highlight
its potential impact on pregnancy outcomes. Interesting
new ﬁndings show that a high-fat meal induces low-
gradeendotoxaemiaandresultsinincreasedexpressionof
markers of endothelial dysfunction potentially via TLR
(Toll-like receptor) signalling pathways [50]. In view of
themacrophageinﬁltrationofadiposetissueandplacenta
in obese pregnancy, this new link between fatty acid
handling, inﬂammation and endothelial dysfunction is
worth pursuing. Finally, there is very little information
on the impact of maternal diet on maternal metabolism
in pregnancy and diets may vary greatly between
the non-obese and obese. Diet has huge potential to
affect the maternal response to pregnancy that may
have downstream effects in the offspring such as those
observed in animal studies [42,49]. More detailed studies
of potential dietary determinants of maternal response
to pregnancy, their interaction with the innate immune
system and their consequences are required.
CLINICAL IMPACT
Up to one in ﬁve women of reproductive age are
obese with signiﬁcant socioeconomic costs directly
attributabletotheincreasedriskofmaternalandneonatal
complications [51]. Direct evidence for lipotoxicity in
obese pregnancy, which may link maternal obesity and
placentallyrelatedadversepregnancyoutcome,islacking.
The placenta may transmit metabolic abnormalities
resulting from lipotoxicity to the offspring via in utero
programming and hence there could be far-reaching con-
sequences for offspring health. Because of the potential
for harm to both mother and baby, a study of the degree,
causes and impact of lipotoxicity in obese pregnancy
is timely. Research in the ﬁelds of cardiovascular and
diabetic medicine suggest ways of manipulating lipid
metabolism using both lifestyle and pharmacological
interventions that may have potential utility in obese
pregnancy. Finally, if our hypotheses are proven correct,
the work would give additional incentives for mothers
to improve their metabolic status (i.e. reduce their waist
circumferences) in advance of becoming pregnant for
beneﬁts both to themselves and their offspring.
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